Special Issue "Pharmaceutical and Nutraceutical Manipulation of Gut Microbiota: Focus on Microbiome Characterization, Pharmacology, Diagnostics and Therapeutic Indications"
Deadline for manuscript submissions: 30 April 2023 | Viewed by 1138
Interests: gut microbiome; inflammatory bowel diseases; 16S rRNA sequencing; brain-gut axis; probiotics; metagenomics; gut homeostasis; systems biology; bacterial genomics
Special Issues, Collections and Topics in MDPI journals
Over the past two decades, advances in omics technology have allowed comprehensive characterizations of the gut microbiome in many health disorders. Gut microbiomes interact with the host through their metabolites, defense against pathogens, and/or immunological promotion. Perturbation of host–microbiome crosstalk has been associated with different health disorders, including irritable bowel syndrome, inflammatory bowel diseases, diabetes, Clostridium difficile infection, and mental health disorders, in addition to the medications used to treat these disorders, such as antidepressants. While some therapeutics, such as some antivirals, are metabolized by the gut microbiota, others, such as antidepressants, affect the gut microbiota diversity. Therefore, the focus of interest of the current wave of microbiome research is investigating how to manipulate the gut microbiome consortium to promote human health and augment the efficiency of other therapeutics. Manipulation of the gut microbiome can be achieved through restoring microbiota diversity and composition or inducing certain functional activities. Several targeted and non-targeted approaches are being tested for their efficiency in modulating the microbiome balance. These approaches include fecal microbiota transplant (FMT) and prebiotic, probiotic, and CRISPR-Cas9-engineered phage. In addition, xenobiotics–gut microbiota interaction is bidirectional. The purpose of this Special Issue is to create a collection of scientific reports that help us to understand the microbiome’s therapeutic potential in different disorders. We invite original articles and extensive reviews in the areas of microbiome characterization, biomarker identification, microbiome pharmacodynamics and pharmacokinetics, and microbiome-based therapeutic manipulations. Any type of article on host–microbiome crosstalk is welcome.
This collection is the second edition of the previous one "Gut Microbiome Manipulation: Focus on Microbiome Characterization, Diagnostics and Therapeutic Indications": https://www.mdpi.com/journal/biology/special_issues/GMMFOMCDATI.
Dr. Walid Mottawea
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gut microbiome
- microbiome pharmacodynamics and pharmacokinetics
- fecal microbiota therapy
- microbiome therapeutics